Evotec expands presence in Italy with acquisition of former GlaxoSmithKline R&D site
Germany-based Evotec established its presence in Italy four years ago. Now, it’s bought up more real estate in the neighborhood.
Evotec has acquired an R&D site in Verona from GSK, the company announced Thursday. The company did not disclose financial details of the deal.
GSK used the site for the specialized manufacturing of finished dose form of cephalosporin. It features sterile powder fill to vials, monorails and Add-Vantage vials and flexible packaging lines. It’s approved by the FDA and EMA, as well as and has maintained global regulatory approvals.
The campus will be renamed the Campus Levi-Montalcini, in honor of Italian Nobel laureate Rite Levi-Montalcini. Levi-Montalcini was awarded the Nobel Prize in 1986 for her work in neurobiology, along with colleague Stanley Cohen, for the discovery of nerve growth factor. She died in December 2012. The name was voted for by employees.
In 2017, Evotec acquired Aptuit, and has been operating out of its Verona campus. The newest acquisition is about three miles away.
“The acquisition of the Verona R&D campus from GSK, one of the major R&D centres in the country, means continuity and further development of R&D excellence in Italy,” Ciriaco Maraschiello, global head of development, said in a statement. “Becoming the owner of the Verona R&D facility strengthens Evotec’s fully integrated R&D solutions for our partners.”
The company, which is based out of Germany, has spread its footprint throughout Europe as of late. In May, the company partnered with Bristol Myers Squibb to launch beLAB1407, a $20 million academic BRIDGE to develop early-stage therapeutic concepts from the universities of Birmingham, Edinburgh, Nottingham, and Dundee, the companies said. The goal is to take the science from these companies and turn them into spinoff companies, using Evotec’s platform.
In April, Evotec announced that it would lay out $120 million to build a new biologics facility in Toulouse, France, to expand production capacity for therapeutic antibodies. That move was boosted by a $60 million investment from several French governments and investors. The company has partnered with the US Department of Defense and the Bill & Melinda Gates Foundation to amp up production of antibodies.
Social image: Werner Lanthaler, Evotec